GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » StemRIM Inc (TSE:4599) » Definitions » Cash, Cash Equivalents, Marketable Securities

StemRIM (TSE:4599) Cash, Cash Equivalents, Marketable Securities : 円7,662.39 Mil (As of Jan. 2025)


View and export this data going back to 2019. Start your Free Trial

What is StemRIM Cash, Cash Equivalents, Marketable Securities?

StemRIM's quarterly cash, cash equivalents, marketable securities declined from Apr. 2024 (円8,738.87 Mil) to Jul. 2024 (円8,410.45 Mil) but then stayed the same from Jul. 2024 (円8,410.45 Mil) to Jan. 2025 (円7,662.39 Mil).

StemRIM's annual cash, cash equivalents, marketable securities increased from Jul. 2022 (円8,880.19 Mil) to Jul. 2023 (円10,217.76 Mil) but then declined from Jul. 2023 (円10,217.76 Mil) to Jul. 2024 (円8,410.45 Mil).


StemRIM Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for StemRIM's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StemRIM Cash, Cash Equivalents, Marketable Securities Chart

StemRIM Annual Data
Trend Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial 10,675.24 10,172.22 8,880.19 10,217.76 8,410.45

StemRIM Quarterly Data
Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Jan25
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9,787.37 9,183.94 8,738.87 8,410.45 7,662.39

StemRIM Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


StemRIM  (TSE:4599) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


StemRIM Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of StemRIM's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


StemRIM Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » StemRIM Inc (TSE:4599) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
N/A
Address
7-15 Ayato Bio Incubator 3rd floor, Ayato Asagi 7-chome, Prefecture Ibaraki City, Osaka, JPN, 567-0085
StemRIM Inc is a biotechnology company engaged in developing regeneration-guided medicines. The business activity of the group includes research, development, manufacture, and sales of pharmaceuticals and medical devices and products such as gene therapy that activate stem cells existing in the body and induce regeneration of damaged tissue.

StemRIM Headlines

No Headlines